Head-to-head evidence
Ciclesonide (XRP1526) vs fluticasone propionate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Ciclesonide (XRP1526)
Developed by Sanofi
NCT00174720 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial, 708 patients with asthma were randomized to one of several ciclesonide dosing regimens or placebo. Ciclesonide produced significantly greater improvements in lung function (FEV1) than placebo, both averaged over weeks 12-16 and at week 16 alone.
fluticasone propionate
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The study was randomized and double-blind, included 908 participants, and compared fluticasone-based treatments with placebo. However, its primary measure was a pulmonary-function surrogate rather than a hard clinical or endoscopic outcome, and the registry does not report whether the primary comparison was met.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciclesonide (XRP1526)'s landscape · fluticasone propionate's landscape